Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Rating of "Hold" from Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have earned a consensus rating of "Hold" from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $4.78.

A number of research firms recently weighed in on IRWD. Citizens Jmp downgraded shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday, April 14th. Jefferies Financial Group reissued a "hold" rating and set a $0.70 price target (down from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Leerink Partners dropped their price target on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a research note on Monday, April 14th. Craig Hallum cut shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $1.00 price objective (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th.

Ironwood Pharmaceuticals Trading Down 6.1%

IRWD stock traded down $0.05 during trading on Wednesday, hitting $0.73. 5,054,807 shares of the stock traded hands, compared to its average volume of 2,562,654. Ironwood Pharmaceuticals has a one year low of $0.53 and a one year high of $7.11. The stock has a market cap of $118.27 million, a price-to-earnings ratio of -3.65 and a beta of 0.24. The company has a 50 day simple moving average of $0.71 and a 200 day simple moving average of $1.85.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative net margin of 9.89% and a negative return on equity of 1.87%. The firm had revenue of $41.14 million for the quarter, compared to the consensus estimate of $67.02 million. As a group, analysts predict that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Inspire Investing LLC boosted its stake in shares of Ironwood Pharmaceuticals by 159.7% during the 1st quarter. Inspire Investing LLC now owns 231,825 shares of the biotechnology company's stock worth $341,000 after buying an additional 142,574 shares during the last quarter. Strs Ohio bought a new stake in Ironwood Pharmaceuticals during the first quarter worth $113,000. McAdam LLC acquired a new stake in Ironwood Pharmaceuticals in the first quarter valued at $40,000. Acadian Asset Management LLC grew its position in shares of Ironwood Pharmaceuticals by 160.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,645,189 shares of the biotechnology company's stock valued at $3,878,000 after acquiring an additional 1,630,726 shares during the period. Finally, Jane Street Group LLC increased its stake in shares of Ironwood Pharmaceuticals by 740.5% during the 1st quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company's stock worth $5,160,000 after purchasing an additional 3,092,475 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.